Alaunos Therapeutics (TCRT) Change in Account Payables (2009 - 2026)
Alaunos Therapeutics (TCRT) reported Change in Account Payables of -$212000.0 for Q1 2026, down 167.3% on a YoY basis from $315000.0 in Q1 2025, and up 7.83% quarter-over-quarter from -$230000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Change in Account Payables (2009 - 2026) Analysis & Trends
Alaunos Therapeutics has reported Change in Account Payables for 18 years, with the latest figure at -$212000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 167.3% year-over-year to -$212000.0; the trailing twelve-month figure through Mar 2026 stood at -$430000.0 (down 283.76% YoY), and the FY2025 full-year result was $97000.0, up 197.0% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$212000.0, up from -$230000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.5 million in Q3 2022, with the low at -$763000.0 in Q1 2022.
- Historically, Change in Account Payables has averaged -$59588.2 across 5 years, with a median of -$110000.0 in 2023.
- The largest YoY upside for Change in Account Payables was 1757.89% in 2025 against a maximum downside of 489.83% in 2025.
- Alaunos Therapeutics' Change in Account Payables stood at -$641000.0 in 2022, then decreased by 6.24% to -$681000.0 in 2023, then jumped by 108.66% to $59000.0 in 2024, then slumped by 489.83% to -$230000.0 in 2025, then rose by 7.83% to -$212000.0 in 2026.
- The last three Change in Account Payables figures came in at -$212000.0 (Q1 2026), -$230000.0 (Q4 2025), and $34000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Alaunos Therapeutics | 4.31 Mn | 3.95 Mn | - | -212,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212,000.00 |
| Mar 31, 2026 | -212,000.00 |
| Dec 31, 2025 | -230,000.00 |
| Dec 31, 2025 | -230,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | -22,000.00 |
| Jun 30, 2025 | -22,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | -232,000.00 |
| Jun 30, 2024 | -232,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Dec 31, 2023 | -681,000.00 |
| Dec 31, 2023 | -681,000.00 |